Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 15Lymphoma 7Lymphoma, Follicular 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Lymphoma, Non-Hodgkin 3Waldenstrom Macroglobulinemia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, B-Cell, Marginal Zone 1Diffuse Large B-Cell Lymphoma Refractory 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 54Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 33Bortezomib 33Whole-Body Irradiation 32ibrutinib 29Dexamethasone 27Tacrolimus 25Cyclosporine 25Etoposide 22Busulfan 22Melphalan 20Filgrastim 20Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16zanubrutinib 14Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Cyclosporins 9idelalisib 8Indium 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Waldenstrom Macroglobulinemia × loncastuximab tesirine × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT02669017 2021-05-19

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

ADC Therapeutics S.A.

Phase 1 Completed
183 enrolled 38 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡